HERE WE are peeking out from the bunker and all we see is biowreckage. The AMEX Biotechnology Index is down about 30% since the beginning of the year and last year’s high-flying genomic stocks are lying there smoldering with the likes of Amgen and Immunex. What’s a CEO to do?

Well, for one, don’t despair. In this case, what looks broken does not need repair. The entire market has gotten crushed and young genomics companies could do very little to avoid getting taken down with the rest of the market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.